6. Able to operate the TTF independently or with the help of a caregiver;
7. Subjects of childbearing potential had to agree to use effective contraception for the duration of the trial;
8. Voluntarily signed the informed consent form.
1. platelet count \< 100×103/μL;
2. absolute neutrophil count \< 1.5×103/μL;
d. AST or ALT exceeding 2.5 times the upper limit of normal; c.Total bilirubin more than 1.5 times the upper limit of the normal range; d.Severe renal impairment (serum creatinine \>1.7 mg/dL, or \>150 μmol/L);
6. There were infection, ulcer and unhealed wound in the skin where the electrode was applied；
7. Patients allergic to conductive hydrogels or medical adhesives;
8. Those who are pregnant or preparing to become pregnant or who are breastfeeding;
9. Patients with poor compliance, as judged by the investigator, or other factors considered by the investigator to be not suitable for the study.
You may not be if
1. Positive driver genes;
2. Recurrent brain metastasis of NSCLC;
3. Suffering from severe cerebral edema;
4. Leptomeningeal metastases;
Clareo Health | Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.
